#439.1: From Lag to Lead: Accelerating Global Innovative Medicines Through China’s NMPA
Monday, June 15, 2026 2:30 PM to 3:30 PM · 1 hr. (America/New_York)
203AB
08: RegPolicy-Strategy-GlobalCollaboration
Information
China is reshaping global drug development and regulatory strategy. This session equips MNC regulatory leaders with decision framework, actionable strategies, pathway insights, and case studies to optimize China integration and global approvals.
CE
ACPECMERN
Session Level
Advanced
Learning Objectives
Assess China’s evolving regulatory landscape to inform global portfolio strategy; Examine National Medical Products Administration (NMPA) regulatory pathways to optimize timelines and market entry; Apply decision frameworks and practical approaches to integrate China into global programs while balancing global alignment, local requirements, and execution risk.
